In addition, we show that a unique advantage of the STIF architecture is the ability to custom-develop genetically encoded sensors to detect various subcellularly (mis)localized proteins in a quantitative manner, such as the BCR-ABL fusion protein of chronic myelogenous leukemia (CML). This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.